Optimized acriflavine-loaded lipid nanocapsules as a safe and effective delivery system to treat breast cancer

Yoann Montigaud, Bernard Ucakar, Balaji Krishnamachary, Zaver M Bhujwalla, Olivier Feron, Véronique Préat, Fabienne Danhier, Bernard Gallez, Pierre Danhier

Research output: Contribution to journalArticle

Abstract

Acriflavine (ACF) hydrochloride is currently repurposed as multimodal drug, inhibiting hypoxia-inducible factors (HIF) pathways and exerting cytotoxic properties. The aim of this study was to encapsulate ACF in reverse micelles and to incorporate this suspension in lipid nanocapsules (LNC). Designs of experiments were used to work under quality by design conditions. LNC were formulated using a phase-inversion temperature method, leading to an encapsulation efficiency around 80%. In vitro, the encapsulated drug presented similar cytotoxic activity and decrease in HIF activity in 4T1 cells compared to the free drug. In vivo, ACF-loaded nanoparticles (ACF dose of 5 mg/kg) demonstrated a higher antitumor efficacy compared to free ACF on an orthotopic model of murine breast cancer (4T1 cells). Moreover, the use of LNC allowed to drastically decrease the number of administrations compared to the free drug (2 versus 12 injections), suppressing the ACF-induced toxicity.

Original languageEnglish (US)
Pages (from-to)322-328
Number of pages7
JournalInternational Journal of Pharmaceutics
Volume551
Issue number1-2
DOIs
StatePublished - Nov 15 2018

Fingerprint

Acriflavine
Nanocapsules
Breast Neoplasms
Lipids
Pharmaceutical Preparations
Micelles
Nanoparticles
Suspensions
Injections
Temperature

Keywords

  • 4T1 cells
  • Acriflavine
  • Breast cancer
  • Design of experiments (DoE)
  • Drug delivery system
  • Lipid nanocapsules

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Optimized acriflavine-loaded lipid nanocapsules as a safe and effective delivery system to treat breast cancer. / Montigaud, Yoann; Ucakar, Bernard; Krishnamachary, Balaji; Bhujwalla, Zaver M; Feron, Olivier; Préat, Véronique; Danhier, Fabienne; Gallez, Bernard; Danhier, Pierre.

In: International Journal of Pharmaceutics, Vol. 551, No. 1-2, 15.11.2018, p. 322-328.

Research output: Contribution to journalArticle

Montigaud, Yoann ; Ucakar, Bernard ; Krishnamachary, Balaji ; Bhujwalla, Zaver M ; Feron, Olivier ; Préat, Véronique ; Danhier, Fabienne ; Gallez, Bernard ; Danhier, Pierre. / Optimized acriflavine-loaded lipid nanocapsules as a safe and effective delivery system to treat breast cancer. In: International Journal of Pharmaceutics. 2018 ; Vol. 551, No. 1-2. pp. 322-328.
@article{44e5eb0a7c704289892b5f1f5a1f1cae,
title = "Optimized acriflavine-loaded lipid nanocapsules as a safe and effective delivery system to treat breast cancer",
abstract = "Acriflavine (ACF) hydrochloride is currently repurposed as multimodal drug, inhibiting hypoxia-inducible factors (HIF) pathways and exerting cytotoxic properties. The aim of this study was to encapsulate ACF in reverse micelles and to incorporate this suspension in lipid nanocapsules (LNC). Designs of experiments were used to work under quality by design conditions. LNC were formulated using a phase-inversion temperature method, leading to an encapsulation efficiency around 80{\%}. In vitro, the encapsulated drug presented similar cytotoxic activity and decrease in HIF activity in 4T1 cells compared to the free drug. In vivo, ACF-loaded nanoparticles (ACF dose of 5 mg/kg) demonstrated a higher antitumor efficacy compared to free ACF on an orthotopic model of murine breast cancer (4T1 cells). Moreover, the use of LNC allowed to drastically decrease the number of administrations compared to the free drug (2 versus 12 injections), suppressing the ACF-induced toxicity.",
keywords = "4T1 cells, Acriflavine, Breast cancer, Design of experiments (DoE), Drug delivery system, Lipid nanocapsules",
author = "Yoann Montigaud and Bernard Ucakar and Balaji Krishnamachary and Bhujwalla, {Zaver M} and Olivier Feron and V{\'e}ronique Pr{\'e}at and Fabienne Danhier and Bernard Gallez and Pierre Danhier",
year = "2018",
month = "11",
day = "15",
doi = "10.1016/j.ijpharm.2018.09.034",
language = "English (US)",
volume = "551",
pages = "322--328",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Optimized acriflavine-loaded lipid nanocapsules as a safe and effective delivery system to treat breast cancer

AU - Montigaud, Yoann

AU - Ucakar, Bernard

AU - Krishnamachary, Balaji

AU - Bhujwalla, Zaver M

AU - Feron, Olivier

AU - Préat, Véronique

AU - Danhier, Fabienne

AU - Gallez, Bernard

AU - Danhier, Pierre

PY - 2018/11/15

Y1 - 2018/11/15

N2 - Acriflavine (ACF) hydrochloride is currently repurposed as multimodal drug, inhibiting hypoxia-inducible factors (HIF) pathways and exerting cytotoxic properties. The aim of this study was to encapsulate ACF in reverse micelles and to incorporate this suspension in lipid nanocapsules (LNC). Designs of experiments were used to work under quality by design conditions. LNC were formulated using a phase-inversion temperature method, leading to an encapsulation efficiency around 80%. In vitro, the encapsulated drug presented similar cytotoxic activity and decrease in HIF activity in 4T1 cells compared to the free drug. In vivo, ACF-loaded nanoparticles (ACF dose of 5 mg/kg) demonstrated a higher antitumor efficacy compared to free ACF on an orthotopic model of murine breast cancer (4T1 cells). Moreover, the use of LNC allowed to drastically decrease the number of administrations compared to the free drug (2 versus 12 injections), suppressing the ACF-induced toxicity.

AB - Acriflavine (ACF) hydrochloride is currently repurposed as multimodal drug, inhibiting hypoxia-inducible factors (HIF) pathways and exerting cytotoxic properties. The aim of this study was to encapsulate ACF in reverse micelles and to incorporate this suspension in lipid nanocapsules (LNC). Designs of experiments were used to work under quality by design conditions. LNC were formulated using a phase-inversion temperature method, leading to an encapsulation efficiency around 80%. In vitro, the encapsulated drug presented similar cytotoxic activity and decrease in HIF activity in 4T1 cells compared to the free drug. In vivo, ACF-loaded nanoparticles (ACF dose of 5 mg/kg) demonstrated a higher antitumor efficacy compared to free ACF on an orthotopic model of murine breast cancer (4T1 cells). Moreover, the use of LNC allowed to drastically decrease the number of administrations compared to the free drug (2 versus 12 injections), suppressing the ACF-induced toxicity.

KW - 4T1 cells

KW - Acriflavine

KW - Breast cancer

KW - Design of experiments (DoE)

KW - Drug delivery system

KW - Lipid nanocapsules

UR - http://www.scopus.com/inward/record.url?scp=85053841103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053841103&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2018.09.034

DO - 10.1016/j.ijpharm.2018.09.034

M3 - Article

C2 - 30236645

AN - SCOPUS:85053841103

VL - 551

SP - 322

EP - 328

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -